Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Business Wire India LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, today ...

Vertex Pharmaceuticals is a global biotechnology ... Smart Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money ...

With surging crime rates, acute security staffing shortages, and mounting false alarms, organisations are desperately seeking ...

Now, more than 122 years after it was first proposed, Kamata and two other mathematicians have finally proved that a solution ...

This crypto market today piece looks at why popular DEX tokens like CAKE, HYPE, and UNI prices are doing well after the FOMC ...

The ASX took a hit on tariff fears with markets dropping globally. Gold soared to new highs and eyes turn to the RBA’s rate decision.

Learn more about whether Elastic N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ ... averaging 7% higher annual returns. Investors are on edge as trade policies shake up the market, ...